Lavoltidine
Lavoltidine (INN, USAN, BAN; previously known as loxtidine, code name AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline) as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.
Wikipage redirect
primaryTopic
Lavoltidine
Lavoltidine (INN, USAN, BAN; previously known as loxtidine, code name AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline) as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.
has abstract
25بك هذه المقالة تحتاج للمزيد ...... رام سرطانية معدية عند القوارض.
@ar
Lavoltidine (INN, USAN, BAN; p ...... c carcinoid tumors in rodents.
@en
ATC prefix
CAS number
76956-02-0
FDA UNII code
X16K5179V5
IUPAC name
[1-methyl-5-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]-1,2,4-triazol-3-yl]methanol
@en
PubChem
thumbnail
Wikipage page ID
26,920,650
Wikipage revision ID
699,782,032
ChemSpiderID
legal status
Development terminated
molecular weight
routes of administration
comment
25بك هذه المقالة تحتاج للمزيد ...... رام سرطانية معدية عند القوارض.
@ar
Lavoltidine (INN, USAN, BAN; p ...... c carcinoid tumors in rodents.
@en
label
Lavoltidine
@en
لوكستيدين
@ar
